Full house of lenders back CCM Pharma's repricing
CCM Pharma has completed its debt repricing, after the company’s existing group of lenders unanimously consented to the changes in an early bird phase.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast